General survival (OS) and progression-free survival (PFS) outcomes with tislelizumab (Tizveni) plus chemotherapy, as outlined by Tumor Space Positivity (TAP) rating and mixed...
Sung, H. et al. International most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations....
Cohort inhabitantsMetastasis and recurrence are necessary elements that lower survival time in AGC. If metastasis or recurrence could be predicted, extra aggressive therapy...
